Oral mucositis is one of the most frequent symptoms in cancer treatment or patients undergoing stem cell transplantation
,9 and this may influence long-term treatments negatively.10 Mucositis occurs one week after the onset of treatment and recovers in about 21 days.11 Therefore, oral mucosa needs to be protected as the treatment gets started.
Bretagne, "Real-time PCR for diagnosis and follow-up of Toxoplasma reactivation after allogeneic stem cell transplantation
using fluorescence resonance energy transfer hybridization probes," Journal of Clinical Microbiology, vol.
In conclusion, allogeneic stem cell transplantation
is a curative approach in many diseases.
Patients undergoing hematopoietic stem cell transplantation
require assistance with symptom control and for dealing with side effects in order to avoid negative effects of their physical condition, social/family status, emotional status, functional status, and additional detrimental effects on their quality of life.
Roh, "Human neural stem cell transplantation
promotes functional recovery in rats with experimental intracerebral hemorrhage," Stroke, vol.
* The report provides a snapshot of the global therapeutic landscape of Hematopoietic Stem Cell Transplantation
To carry out limbal stem cell transplantation
in various ocular surface disorders.
Finally, 29 patients received BM stem cell transplantation
, 100 patients were performed with peripheral blood stem cell transplantation
, and the other 6 patients' stem cells came from BM and peripheral blood.
As per the National Guidelines for Stem Cell Research 2013, stem cell therapy has not been proven effective other than in Hematopoietic Stem Cell Transplantation
( HSCT) for haematological disorders ( disorders which primarily affect the blood).
Key words: Childhood, hematopoetic stem cell transplantation
, cord blood transplantation
It includes discussion of the rationale for transplantation, types, evaluation and counseling of patients and donors, preventative care, graft-versus-host disease, special transfusion-related situations, regulation and accreditation, and conditioning regimens, as well as a new chapter on oral health in stem cell transplantation
CliniMACS Biotec, Cambridge, MA and Bergisch Gladbach, Germany, announced the US Food and Drug Administration has approved the company's CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft-versus-host disease (GvHD) in patients with acute myeloid leukemia (AMS) in first complete remission undergoing allogeneic stem cell transplantation
(SCT) from a matched related donor.